These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
4. Doctors are focus of some sweeping changes being dusted off in Drug Reform Act. Hornett P Leg Aspects Med Pract; 1978 Aug; 6(8):54-7. PubMed ID: 703483 [No Abstract] [Full Text] [Related]
5. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
6. ASHP guidelines for institutional use of controlled substances. Am J Hosp Pharm; 1974 Jun; 31(6):582-8. PubMed ID: 4407475 [No Abstract] [Full Text] [Related]
7. American Pharmaceutical Association House of Delegates, May 13-18, 1978, Montreal, Quebec, Canada. Report of the Policy Committee on Organizational Affairs. Am Pharm; 1978 Jul; 18(8 Spec No):32-5. PubMed ID: 665505 [No Abstract] [Full Text] [Related]
8. The brand name system--an intrusion upon the profession. Feldmann EG J Am Pharm Assoc; 1971 Jul; 11(7):376-9 passim. PubMed ID: 5142132 [No Abstract] [Full Text] [Related]
10. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
12. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products. Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700 [No Abstract] [Full Text] [Related]
13. Government investigations in the pharmaceutical industry: off-label promotion, fraud and abuse, and false claims. Kalb PE; Bass IS Food Drug Law J; 1998; 53(1):63-70. PubMed ID: 11795337 [No Abstract] [Full Text] [Related]
14. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption. Poser S Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225 [No Abstract] [Full Text] [Related]
15. New drug development in the changing health care environment: a panel discussion. Flanagan A; Temple RJ; Wardell WM Ann N Y Acad Sci; 1981; 368():203-11. PubMed ID: 6942776 [No Abstract] [Full Text] [Related]
16. The case for preemption of prescription drug failure-to-warn claims. Kim CH Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969 [No Abstract] [Full Text] [Related]